{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:06:28Z","timestamp":1791950788996,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.critrevonc.2024.104306","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T11:15:28Z","timestamp":1708686928000},"page":"104306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Filgrastim biosimilar (EP2006): A review of 15 years\u2019 post-approval evidence"],"prefix":"10.1016","volume":"196","author":[{"given":"Pere","family":"Gasc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.critrevonc.2024.104306_bib1","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1002\/cam4.2955","article-title":"Mortality and admission to intensive care units after febrile neutropenia in patients with cancer","volume":"9","author":"Aagaard","year":"2020","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1078155211407367","article-title":"Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia","volume":"18","author":"Aapro","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jgo.2016.09.006","article-title":"Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: patterns, outcomes, and determinants (MONITOR-GCSF study)","volume":"8","author":"Aapro","year":"2017","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104306_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918768419","article-title":"Development and 10-year history of a biosimilar: the example of Binocrit\u00ae","volume":"10","author":"Aapro","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00520-023-08043-4","article-title":"Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer","volume":"31","author":"Aapro","year":"2023","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2024.104306_bib6","unstructured":"Aghedo, B.O., Gupta, V., 2022. Filgrastim. [Updated 2023 Jul 3]. In: StatPearls [Internet]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559282\/ (Accessed 27 November 2023)."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib7","first-page":"128","article-title":"Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis","volume":"29","author":"Aslam","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00520-020-05715-3","article-title":"Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice","volume":"29","author":"Averin","year":"2021","journal-title":"Support. Care Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104306_bib9","first-page":"478","article-title":"Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens","volume":"13","author":"Bassi","year":"2015","journal-title":"Blood Transfus."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216835","article-title":"Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia","volume":"14","author":"Baugh","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104306_bib11","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1111\/trf.13853","article-title":"Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance","volume":"56","author":"Becker","year":"2016","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104306_bib12","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdv281","article-title":"Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Blackwell","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/annonc\/mdx638","volume":"29","author":"Blackwell","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00520-017-3572-4","article-title":"Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study","volume":"25","author":"Bokemeyer","year":"2017","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00520-016-3390-0","article-title":"Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR)","volume":"25","author":"Bongiovanni","year":"2017","journal-title":"Support. Care Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104306_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","article-title":"G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review","volume":"15","author":"Campbell","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104306_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1151764","article-title":"Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends","volume":"14","author":"Car","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104306_bib18","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.transproceed.2014.09.070","article-title":"Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation","volume":"46","author":"Cioch","year":"2014","journal-title":"Transplant. Proc."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/2159-8290.CD-ND2015-002","article-title":"FDA approves first biosimilar, zarxio","volume":"5","author":"Colwell","year":"2015","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104306_bib20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2217\/fon-2018-0762","article-title":"The evolution of value with filgrastim in oncology","volume":"15","author":"Cornes","year":"2019","journal-title":"Future Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.critrevonc.2024.104306_bib21","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2008.10.014","article-title":"Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization","volume":"72","author":"Crea","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1078155220941582","article-title":"Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization","volume":"27","author":"Curry","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clml.2017.05.002","article-title":"ZOH\u00e9: a prospective study of the use of biosimilar filgrastim Zarzio in clinical practice in patients treated with chemotherapy for lymphoid malignancies","volume":"17","author":"Damaj","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","volume":"16","author":"Dulisse","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.critrevonc.2024.104306_bib26","unstructured":"European Medicines Agency, 2017. Biograstim Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/biograstim#product-information-section (Accessed 23 August 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib27","unstructured":"European Medicines Agency, 2019. Biosimilars in the EU: Information guide for healthcare professionals. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf\u3009 (Accessed 27 November)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib28","unstructured":"European Medicines Agency, 2023a. Accofil Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/accofil#product-information-section\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib29","unstructured":"European Medicines Agency, 2023b. Grastofil Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/grastofil#product-information-section\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib30","unstructured":"European Medicines Agency, 2023c. Nivestim Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nivestim#product-information-section\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib31","unstructured":"European Medicines Agency, 2023d. Zarzio Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zarzio#product-information-section\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib32","unstructured":"European Medicines Agency, 2023e. Tevagrastim Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tevagrastim#product-information-section\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib33","unstructured":"European Medicines Agency, 2023f. Filgrastim Hexal Summary of Product Characteristics. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/filgrastim-hexal#product-information-section\u3009 (Accessed 27 November 2023)."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00277-017-3060-4","article-title":"Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors","volume":"96","author":"Farhan","year":"2017","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104306_bib35","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","article-title":"Development of a new G-CSF product based on biosimilarity assessment","volume":"21","author":"Gascon","year":"2010","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib36","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00520-013-1911-7","article-title":"Clinical experience with Zarzio\u00ae in Europe: what have we learned?","volume":"21","author":"Gascon","year":"2013","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","article-title":"Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)","volume":"24","author":"Gascon","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40259-019-00373-2","article-title":"Extrapolation in practice: lessons from 10 years with biosimilar filgrastim","volume":"33","author":"Gascon","year":"2019","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40261-018-0637-1","article-title":"Epoetin biosimilars in the treatment of renal anemia: what have we learned from a decade of European experience?","volume":"38","author":"Goldsmith","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1634\/theoncologist.2017-0348","article-title":"Safety profile of biosimilar filgrastim (Zarzio\/Zarxio): a combined analysis of phase III studies","volume":"23","author":"Harbeck","year":"2018","journal-title":"Oncologist"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104306_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.2018.36.15_suppl.111","article-title":"Comparison of efficacy and safety of biosimilar filgrastim in a RCT (PIONEER) and real-world practice (MONITOR-GCSF)","volume":"36","author":"Harbeck","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104306_bib42","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2002-07-2062","article-title":"Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells","volume":"101","author":"Hermans","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12967-022-03322-w","article-title":"Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation","volume":"20","author":"Heyn","year":"2022","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/14712598.2016.1128410","article-title":"Totality of the evidence at work: the first U.S. biosimilar","volume":"16","author":"Holzmann","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2024.104306_bib45","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.938585","volume":"28","author":"Islami","year":"2023","journal-title":"Ann. Transplant."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104306_bib46","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1377\/hlthaff.2019.00253","article-title":"Biosimilar filgrastim uptake and costs among commercially insured, medicare advantage","volume":"38","author":"Karaca-Mandic","year":"2019","journal-title":"Health Aff. (Millwood)"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/jcpt.12716","article-title":"Power outages and refrigerated medicines: the need for better guidelines, awareness and planning","volume":"43","author":"Kosari","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2024.104306_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.07.009","article-title":"Biosimilars in oncology: a decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies","author":"Krendyukov","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12325-011-0009-1","article-title":"First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor","volume":"28","author":"Lefr\u00e8re","year":"2011","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104306_bib50","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1200\/OP.20.01047","article-title":"Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis","volume":"17","author":"Li","year":"2021","journal-title":"JCO Oncol. Pract."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104306_bib51","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1007\/s00520-022-07103-5","article-title":"Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)","volume":"30","author":"Link","year":"2022","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib52","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00520-018-4513-6","article-title":"Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio\u00ae) initiated \u201csame-day\u201d (<\u200924h), \u201cper-guidelines\u201d (24\u201372\u2009h), and \u201clate\u201d (>\u200972h): findings from the MONITOR-GCSF study","volume":"27","author":"Ludwig","year":"2019","journal-title":"Support. Care Cancer"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104306_bib53","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pharep.2013.09.005","article-title":"A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization","volume":"66","author":"Manko","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/10428194.2015.1063147","article-title":"Biosimilar filgrastim (Zarzio\u00ae) vs. lenograstim (Myelostim\u00ae) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience","volume":"57","author":"Marchesi","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2024.104306_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00277-023-05604-9","article-title":"Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim","volume":"103","author":"Marchesi","year":"2024","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104306_bib57","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","article-title":"Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation","volume":"102","author":"Martino","year":"2023","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib58","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13696998.2017.1358173","article-title":"Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia","volume":"20","author":"McBride","year":"2017","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/13696998.2019.1658591","article-title":"Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma","volume":"23","author":"McBride","year":"2020","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib60","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00520-015-2986-0","article-title":"Zarzio\u00ae, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study","volume":"24","author":"Nahon","year":"2016","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2024.104306_bib61","unstructured":"National Comprehensive Cancer Network, 2023a. NCCN Clinical Practice Guidelines in Oncology \u2013 Hematopoietic Cell Transplantation v1. \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1501\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib62","unstructured":"National Comprehensive Cancer Network, 2023b. NCCN Clinical Practice Guidelines in Oncology \u2013 Hematopoietic Growth Factors v1. \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493\u3009 (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib63","unstructured":"NIH National Library of Medicine - DailyMed database Zarxio Prescribing Information 2022.accessed 27 November 2023\u3008https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy255","article-title":"Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases","volume":"5","author":"Nordvig","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40487-020-00115-3","article-title":"Mobilization of hematopoietic stem cells into peripheral blood for autologous transplantation seems less efficacious in poor mobilizers with the use of a biosimilar of filgrastim and plerixafor: a retrospective comparative analysis","volume":"8","author":"Parody","year":"2020","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.critrevonc.2024.104306_bib66","unstructured":"Pharmaceutical Management Agency, 2014. Annual Review. https:\/\/pharmac.govt.nz\/assets\/annual-review-2014.pdf (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib67","article-title":"G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: a French, multicenter, prospective, non-interventional study","volume":"35","author":"Phelip","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib68","first-page":"660","article-title":"Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018","volume":"27","author":"Qian","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104306_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114976","article-title":"Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: trends from decades of data","volume":"395","author":"Rastogi","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib70","first-page":"1069","article-title":"Efficacy and safety of filgrastim and its biosimilars to prevent febrile neutropenia in cancer patients: a prospective study and meta-analysis","volume":"10","author":"Rastogi","year":"2021","journal-title":"Biology (Basel)"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12325-014-0114-z","article-title":"Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF","volume":"31","author":"Rem\u00e9nyi","year":"2014","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104306_bib72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon.12.32","article-title":"Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF","volume":"8","author":"Salesi","year":"2012","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib73","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/vox.12397","article-title":"Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF","volume":"111","author":"Schmitt","year":"2016","journal-title":"Vox. Sang."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104306_bib74","first-page":"976","article-title":"Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy","volume":"24","author":"Schwartzberg","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104306_bib75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/CEOR.S168298","article-title":"Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar","volume":"10","author":"Schwartzberg","year":"2018","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jval.2019.12.007","article-title":"Biosimilar uptake in Medicare Part B varied across hospital outpatient departments and physician practices: the case of filgrastim","volume":"23","author":"Socal","year":"2020","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/11585100-000000000-00000","article-title":"Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product","volume":"24","author":"S\u00f6rgel","year":"2010","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104306_bib78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40259-015-0124-7","article-title":"Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics","volume":"29","author":"S\u00f6rgel","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.critrevonc.2024.104306_bib79","unstructured":"U.S. Food and Drug Administration, 2021a. Zarxio Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125553s023lbl.pdf (Accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib80","unstructured":"U.S. Food and Drug Administration, 2021b. Nivestym Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761080s007lbl.pdf (accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib81","unstructured":"U.S. Food and Drug Administration, 2022a. Releuko Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761082s003lbl.pdf (accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib82","unstructured":"U.S. Food and Drug Administration, 2022b. Biosimilars \u2013 review and approval. https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval (accessed 27 November 2023)."},{"key":"10.1016\/j.critrevonc.2024.104306_bib83","unstructured":"U.S. Food and Drug Administration, 2023. Neupogen Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/103353s5198lbl.pdf (Accessed 27 November 2023)."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104306_bib84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1758834012461330","article-title":"A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre","volume":"4","author":"Verpoort","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104306_bib85","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/rheumatology\/kev394","article-title":"The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range","volume":"55","author":"Vlieland","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104306_bib86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40266-018-0524-8","article-title":"Older patients' compliance with drug storage recommendations","volume":"35","author":"Vlieland","year":"2018","journal-title":"Drugs Aging"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104306_bib87","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood-2014-06-583617","article-title":"Biosimilars: the science of extrapolation","volume":"124","author":"Weise","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JOP.2014.001492","article-title":"Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors","volume":"11","author":"Weycker","year":"2015","journal-title":"J. Oncol. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jca.21750","article-title":"The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT)","volume":"35","author":"Wicherska-Paw\u0142owska","year":"2020","journal-title":"J. Clin. Apher."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104306_bib90","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/13696998.2023.2183680","article-title":"Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study","volume":"26","author":"Yousef","year":"2023","journal-title":"J. Med. Econ."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104306_bib91","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00520-017-3923-1","article-title":"A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation","volume":"26","author":"Zecchini","year":"2018","journal-title":"Support. Care Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T17:40:24Z","timestamp":1715449224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":91,"alternative-id":["S1040842824000490"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104306","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Filgrastim biosimilar (EP2006): A review of 15 years\u2019 post-approval evidence","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104306"}}